Published in Ann Oncol on October 01, 2010
Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma. Leukemia (2013) 1.08
Impact of the treatment-free interval on health-related quality of life in patients with multiple myeloma: a UK cross-sectional survey. Support Care Cancer (2012) 0.99
Physical activity participation and barriers for people with multiple myeloma. Support Care Cancer (2012) 0.79
The Prognostic Significance of Beta2 Microglobulin in Patients with Hemophagocytic Lymphohistiocytosis. Dis Markers (2016) 0.79
Cancer-testis antigen MAGE-C2/CT10 induces spontaneous CD4+ and CD8+ T-cell responses in multiple myeloma patients. Blood Cancer J (2014) 0.79
Logic-Based and Cellular Pharmacodynamic Modeling of Bortezomib Responses in U266 Human Myeloma Cells. J Pharmacol Exp Ther (2015) 0.76
Treatment of spinal epidural compression due to hematological malignancies: a single institution's retrospective experience. Eur Spine J (2012) 0.76
Abnormal repression of SHP-1, SHP-2 and SOCS-1 transcription sustains the activation of the JAK/STAT3 pathway and the progression of the disease in multiple myeloma. PLoS One (2017) 0.75
Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies. Onco Targets Ther (2017) 0.75
Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas. Br J Haematol (2001) 2.75
Engraftment syndrome after auto-SCT: analysis of diagnostic criteria and risk factors in a large series from a single center. Bone Marrow Transplant (2010) 1.52
Pathogenesis and progression of monoclonal gammopathy of undetermined significance. Leukemia (2008) 1.39
Monoclonal gammopathy of undetermined significance: predictors of malignant transformation and recognition of an evolving type characterized by a progressive increase in M protein size. Mayo Clin Proc (2007) 1.27
Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients. Leukemia (2006) 1.20
Emergence of oligoclonal bands in patients with multiple myeloma in complete remission after induction chemotherapy: association with the use of novel agents. Haematologica (2010) 1.14
High-dose therapy/autologous stem cell transplantation in patients with chemosensitive multiple myeloma: predictors of complete remission. Bone Marrow Transplant (2004) 0.99
Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients. Leukemia (2012) 0.97
Hypercalcemia as the presenting feature of t-cell lymphoid blast crisis of ph-positive chronic myeloid leukemia. Leuk Lymphoma (2001) 0.91
A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control. Leukemia (2013) 0.90
Development of rapidly progressive liver light chain deposition under VAD chemotherapy in multiple myeloma. Eur J Haematol (2006) 0.89
Bortezomib: a valuable new antineoplastic strategy in multiple myeloma. Acta Oncol (2005) 0.89
Management of complications in multiple myeloma. Semin Hematol (2009) 0.88
T1 mapping: characterisation of myocardial interstitial space. Insights Imaging (2014) 0.86
Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment. Clin Lymphoma Myeloma (2008) 0.85
Study of the antibody response against Mycobacterium tuberculosis antigens in Warao Amerindian children in Venezuela. Mem Inst Oswaldo Cruz (2004) 0.84
Prognostic factors for multiple myeloma in the era of novel agents. Ann Oncol (2008) 0.84
Serial intestinal endoscopic examinations of patients with persistent diarrhea after allo-SCT. Bone Marrow Transplant (2011) 0.82
Prognostic impact of serum immunoglobulin heavy/light chain ratio in patients with multiple myeloma in complete remission after autologous stem cell transplantation. Biol Blood Marrow Transplant (2012) 0.82
Response to thalidomide in multiple myeloma: impact of angiogenic factors. Cytokine (2004) 0.81
Primary systemic amyloidosis presenting as a colonic stricture: successful treatment with left hemicolectomy followed by autologous hematopoietic stem-cell transplantation: report of a case. Dis Colon Rectum (2002) 0.79
Thalidomide in refractory and relapsing multiple myeloma. Semin Oncol (2001) 0.77
Idiopathic myelofibrosis associated with primary biliary cirrhosis. Leuk Lymphoma (2002) 0.75
Malignant transformation in IgM monoclonal gammopathy of undetermined significance. Semin Oncol (2003) 0.75